Disclosed herein are new peptide inhibitors against beta-lactam resistance that can improve the efficacy of currently available antibiotics. Methods of using the peptide inhibitors for treating bacterial infections are also disclosed.

The present invention is related to compositions containing extracellular vesicles (exosomes) and methods of using the same for increasing lifespan of fetus, viability of fetus, or viability of newborn, for treating inflammation in uterus and/or fetus, for delaying preterm birth, or for treating a condition related to inflammation in uterus and/or fetus, wherein the extracellular vesicles comprising a nuclear factor kappa beta (NF-κB) inhibitor and a photo-specific binding protein.

The present invention is related to compositions containing extracellular vesicles (exosomes) and methods of using the same for increasing lifespan of fetus, viability of fetus, or viability of newborn, for treating inflammation in uterus and/or fetus, for delaying preterm birth, or for treating a condition related to inflammation in uterus and/or fetus, wherein the extracellular vesicles comprising a nuclear factor kappa beta (NF-κB) inhibitor and a photo-specific binding protein.

Pharmaceutical compositions comprising a β-lactam antibiotic and an avibactam derivative and methods of treating bacterial infections using the pharmaceutical compositions are disclosed. The pharmaceutical compositions can be formulated for oral administration and following oral administration provide a therapeutically effective amount of β-lactam antibiotic and avibactam in the system circulation of a patient. The oral pharmaceutical compositions can methods can be used to treat infections caused by bacteria that produce β-lactamase enzymes.

The invention relates to chemistry and pharmacology, specifically to a synthetic biologically active substance -7,9-dibromo-2,4-dioxo-1,2,3,4-tetrahydrochromeno[2,3-d]-pyrimidinium-10 acetate or succinate formula 1:1

##STR00001## Where X.sup.−═CH.sub.3COO.sup.− or HOOCCH.sub.2CH.sub.2COO.sup.−, as well as its tautomeric, hydrated forms, solvate, complex compounds, adducts and salt forms, possessing antimicrobial activity, and the ability to penetrate bacterial biofilms. The compound is intended for the treatment of bacterial infections of the oropharynx, skin, and mucous membranes, urinary system, implants, respiratory system, gastrointestinal tract. osteomyelitis, sepsis, nosocomial and wound infections.

The invention relates to chemistry and pharmacology, specifically to a synthetic biologically active substance -7,9-dibromo-2,4-dioxo-1,2,3,4-tetrahydrochromeno[2,3-d]-pyrimidinium-10 acetate or succinate formula 1:1

##STR00001## Where X.sup.−═CH.sub.3COO.sup.− or HOOCCH.sub.2CH.sub.2COO.sup.−, as well as its tautomeric, hydrated forms, solvate, complex compounds, adducts and salt forms, possessing antimicrobial activity, and the ability to penetrate bacterial biofilms. The compound is intended for the treatment of bacterial infections of the oropharynx, skin, and mucous membranes, urinary system, implants, respiratory system, gastrointestinal tract. osteomyelitis, sepsis, nosocomial and wound infections.

The present invention relates to the field of medicine, specifically the field of bacterial infection and treatment thereof.

The present invention relates to the field of medicine, specifically the field of bacterial infection and treatment thereof.

Methods for treating a bacterial infections, including drug-resistant bacterial infections, of a patient are described. The methods may include applying a non-thermal plasma and a liquid simultaneously to infected tissue of the patient, the liquid comprising at least one antibiotic and/or antiseptic and a penetration enhancing agent; wherein the non-thermal plasma has a frequency between 200 kHz and 600 kHz.

Methods for treating a bacterial infections, including drug-resistant bacterial infections, of a patient are described. The methods may include applying a non-thermal plasma and a liquid simultaneously to infected tissue of the patient, the liquid comprising at least one antibiotic and/or antiseptic and a penetration enhancing agent; wherein the non-thermal plasma has a frequency between 200 kHz and 600 kHz.